Key Takeaways
- Health Canada has granted Class II clearance to three new long-term cardiac monitoring devices in 2026, expanding the remote care toolkit for cardiologists.
- The three devices cleared include a 14-day patch monitor, a 30-day injectable loop recorder equivalent, and a smartphone-integrated ECG system.
- Remote cardiac monitoring programs targeting atrial fibrillation detection have shown 23% lower 90-day hospital readmission rates in Canadian pilot programs.
- The Canadian cardiac monitoring market is projected to reach $420 million by 2028, growing at 16% annually.
Atrial fibrillation affects approximately 350,000 Canadians, and a significant proportion of strokes estimated at 20-25% are attributable to previously undetected AF. The challenge for Canadian cardiologists has been detection: paroxysmal AF is intermittent, and standard 24-hour Holter monitoring catches only a fraction of episodes that may be causing symptoms or elevating stroke risk. A new generation of long-term wearable cardiac monitoring devices, three of which received Health Canada Class II clearance in the first half of 2026, is changing the detection calculus and expanding a Canadian cardiac monitoring market that is projected to reach $420 million by 2028.
The Three Devices Cleared in 2026
CardioTrace 14 (CardioNet Canada) a waterproof 14-day continuous ECG patch that automatically detects and timestamps arrhythmia events and transmits daily reports to a remote cardiac monitoring centre. The device received Class II clearance in February 2026 and is Health Canada’s first approval for a cloud-connected long-term ECG patch with automated arrhythmia classification. The device’s AI interpretation algorithm achieves 97.3% sensitivity for AF detection versus expert cardiologist review.
RhythmGuard 30 (MedSense Diagnostics) a 30-day extended Holter equivalent using a semi-adhesive chest patch that achieves single-lead ECG quality equivalent to traditional Holter monitors. RhythmGuard 30 received clearance in April 2026 and is targeted at provincial heart function clinic programs seeking to replace traditional Holter monitoring for longer diagnostic windows.
HeartLink Mobile (Cardea Health) a smartphone-integrated ECG system using a hand-held sensor that enables medical-grade, physician-ordered ECG recording. Unlike consumer devices such as Apple Watch or Fitbit, HeartLink Mobile is designed for clinical workflow integration, with FHIR-compliant data transfer to electronic health records and automated interpretation reports. Cleared in May 2026 as a Class II SaMD device.
| Device | Company | Monitoring Duration | HC Clearance Class | Key Clinical Claim | Est. Price/Patient |
|---|---|---|---|---|---|
| CardioTrace 14 | CardioNet Canada | 14 days continuous | Class II | AF detection sensitivity 97.3% | $385 |
| RhythmGuard 30 | MedSense Diagnostics | 30 days | Class II | Equivalent to Holter, 30-day window | $520 |
| HeartLink Mobile | Cardea Health | On-demand + 7-day auto | Class II SaMD | EHR-integrated, prescription workflow | $195 |
| Zio XT (US – iRhythm) | iRhythm Technologies | 14 days | Class II (2024) | Extensive real-world evidence base | $395 |
| AliveCor KardiaMobile 6L | AliveCor | On-demand 6-lead ECG | Class II (2022) | 6-lead medical ECG, physician Rx | $149 device |
Reimbursement: The Provincial Fee Code Challenge
Health Canada clearance establishes safety and effectiveness but does not guarantee payment. Provincial insurance plans reimburse cardiac monitoring through fee codes that were designed for traditional Holter monitoring and event monitoring services and these codes do not always map cleanly onto new digital monitoring modalities. The result is a reimbursement patchwork: Ontario has a fee code for remote cardiac monitoring that covers devices like CardioTrace 14 when ordered by a cardiologist; British Columbia is still developing its billing framework; and Quebec currently reimburses 14-day patch monitors only within designated cardiology clinic programs.
The Canadian Cardiovascular Society and the Canadian Heart Rhythm Society are engaged in active advocacy with provincial health ministries to modernize cardiac monitoring fee codes to reflect the clinical utility of long-term digital monitoring. The advocacy cites health system cost savings from reduced 90-day readmissions estimated at 23% lower in programs with structured remote monitoring protocols as the primary economic justification.
The Bottom Line
The three Health Canada clearances in 2026 expand the wearable cardiac monitoring toolkit available to Canadian cardiologists and provide a regulatory foundation for broader program adoption across provincial health systems. The 23% reduction in 90-day hospital readmissions demonstrated in Canadian pilot programs is a health system cost argument that is difficult for provincial health ministries to ignore indefinitely, and the expected modernization of provincial fee codes will be the catalyst that converts clinical interest into broad commercial deployment. For investors, the question is which of the newly cleared Canadian platforms and which of the established US competitors will dominate the provincial formulary contracts that will define this market through 2030.